利伐沙班片包装图片

(Rivaroxaban) is a highly selective new oral anticoagulant drug that directly inhibits factor

Rivaroxaban is mainly used in clinical practice to prevent venous thrombosis (VTE) formation in adult patients after knee or hip replacement; to treat deep vein thrombosis (DVT), to prevent DVT recurrence and PE after acute DVT; to prevent non-valvular atrial fibrillation (NVAF), stroke and systemic embolism in adult patients.

The drug was launched in China in June 2009. Since its launch, patients have also developed a certain interest in the packaging pictures of Rivaroxaban Tablets (Xarelto). By understanding the drug packaging, they can also lay the foundation for future drug purchases. The pictures are as follows:

The phase III clinical studies related to indications that my country has participated in mainly include RECORD, EINSTEIN and ROCKE studies. The results of the studies show that the therapeutic effect of rivaroxaban is not inferior to vitamin K antagonists or enoxaparin without increasing the risk of bleeding. Although studies have proven that rivaroxaban has clear pharmacodynamics and clinical application does not require dose adjustment based on monitoring indicators, fixed-dose treatment has certain limitations. Undertreatment or drug overdose cannot be effectively monitored or dealt with. Once bleeding occurs, there is no specific reversal agent, so doctors often have concerns when using it and dare not administer the drug in sufficient amounts.

In addition, indicators that can be used to monitor the efficacy of rivaroxaban are also needed in certain special clinical situations, such as drug overdose, active bleeding, bridging heparin, preoperative preparation, or acute renal failure. Moreover, the dosage regimen and dosage of rivaroxaban in the above three indications are different. In clinical practice, the dosage regimen is often formulated according to the patient's thrombotic disease. At this time, indicators are also needed to monitor the efficacy and safety.

Recommended hot articles: /newsDetail/73169.html